🇺🇸 FDA
Pipeline program

Migalastat Hydrochloride Dispersible Tablet

AT1001-033

Phase 3 small_molecule active

Quick answer

Migalastat Hydrochloride Dispersible Tablet for Fabry disease is a Phase 3 program (small_molecule) at Amicus Therapeutics Europe Limited with 1 ClinicalTrials.gov record(s).

Program details

Company
Amicus Therapeutics Europe Limited
Indication
Fabry disease
Phase
Phase 3
Modality
small_molecule
Status
active

Clinical trials